Investigating how immune responses affect heart damage from cancer treatment
Type I Interferon Responses in the Pathobiology of Anthracycline-induced Cardiotoxicity
This study is looking at how a common cancer treatment called doxorubicin can hurt the heart, and it aims to find out how certain signals in the body might lead to this damage, so we can discover ways to predict and prevent heart problems for patients undergoing chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jackson Laboratory NIH-funded |
| Lab location | 1 site (Bar Harbor, United States) |
| Project ID | NIH-10891568 on NIH RePORTER |
What this research studies
This research focuses on understanding the harmful effects of anthracycline chemotherapy, particularly doxorubicin, on the heart. It aims to uncover the mechanisms by which type I interferon signaling contributes to heart damage during and after cancer treatment. By studying how DNA damage in heart cells triggers immune responses, the research seeks to identify potential biomarkers and treatments to predict and prevent cardiotoxicity in patients. The approach involves both laboratory studies and analysis of cardiac responses to chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving anthracycline-based chemotherapy who may be at risk for heart complications.
Not a fit: Patients who are not receiving anthracycline chemotherapy or those with pre-existing severe heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing heart damage in cancer patients undergoing chemotherapy.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune responses in chemotherapy-related side effects, suggesting that this approach could yield valuable insights.
Where this research is happening
Bar Harbor, United States
- Jackson Laboratory — Bar Harbor, United States (Active)
Researchers
- Principal investigator: West, Andrew Phillip — Jackson Laboratory
- Study coordinator: West, Andrew Phillip
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.